Description

The U.S. Influenza Market was valued at US$ 2.7 billion in 2021 and is expected to witness a CAGR of 16.2% over the forecast period 2022–2028 Influenza is an upper respiratory tract disease and is caused by the influenza virus. U.S. Influenza Market is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in geriatric population and children with less than 5 years of age.  The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus’s RNA is more accurate. Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market. In May 2016, Seqirus received approval from U.S. Food and Drug Administration for Flucelvax Quadrivalent, that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older. In November 2016, GSK received approval from U.S. Food and Drug Administration for flulaval Quadrivalent to include use in children aged six months or older

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX